标题
Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma
作者
关键词
-
出版物
LEUKEMIA
Volume 26, Issue 2, Pages 199-213
出版商
Springer Nature
发表日期
2011-08-19
DOI
10.1038/leu.2011.214
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Blockade of CD200 in the Presence or Absence of Antibody Effector Function: Implications for Anti-CD200 Therapy
- (2014) A. Kretz-Rommel et al. JOURNAL OF IMMUNOLOGY
- Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial
- (2011) George Somlo et al. BRITISH JOURNAL OF HAEMATOLOGY
- CD200 expression in plasma cell myeloma
- (2011) Horatiu Olteanu et al. BRITISH JOURNAL OF HAEMATOLOGY
- Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma
- (2011) Sally A. Hunsucker et al. BRITISH JOURNAL OF HAEMATOLOGY
- Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
- (2011) David H. Henry et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma
- (2011) P Moreau et al. LEUKEMIA
- Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies
- (2010) H. M. Horton et al. BLOOD
- The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
- (2010) D. M. Benson et al. BLOOD
- Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers
- (2010) Lei Wu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma
- (2010) M. Hussein et al. HAEMATOLOGICA
- Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab
- (2010) M. S. van der Veer et al. HAEMATOLOGICA
- Establishment of an HS23 stromal cell-dependent myeloma cell line: fibronectin and IL-6 are critical
- (2010) Akira Sakai et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
- (2010) M. de Weers et al. JOURNAL OF IMMUNOLOGY
- Antibody-maytansinoid conjugates for the treatment of myeloma
- (2010) Robert J. Lutz et al. mAbs
- Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease
- (2010) S. Vallet et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma
- (2009) Ravi Vij et al. AMERICAN JOURNAL OF HEMATOLOGY
- The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor
- (2009) Anne Catherine Sprynski et al. BLOOD
- Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells
- (2009) F. Romagne et al. BLOOD
- Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma
- (2009) M. Fulciniti et al. BLOOD
- A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45
- (2009) G Descamps et al. BRITISH JOURNAL OF CANCER
- Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death
- (2009) Peter M. Voorhees et al. BRITISH JOURNAL OF HAEMATOLOGY
- The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo
- (2009) H. Ikeda et al. CLINICAL CANCER RESEARCH
- Combining Milatuzumab with Bortezomib, Doxorubicin, or Dexamethasone Improves Responses in Multiple Myeloma Cell Lines
- (2009) R. Stein et al. CLINICAL CANCER RESEARCH
- A High-Affinity Fully Human Anti-IL-6 mAb, 1339, for the Treatment of Multiple Myeloma
- (2009) M. Fulciniti et al. CLINICAL CANCER RESEARCH
- P-Selectin Glycoprotein Ligand-1 as a Potential Target for Humoral Immunotherapy of Multiple Myeloma (Supplementry Material)
- (2009) C. Tripodo et al. CURRENT CANCER DRUG TARGETS
- FGFR3-targeted mAb therapy for bladder cancer and multiple myeloma
- (2009) Yaron Hadari et al. JOURNAL OF CLINICAL INVESTIGATION
- Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice
- (2009) Jing Qing et al. JOURNAL OF CLINICAL INVESTIGATION
- Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
- (2009) H Quach et al. LEUKEMIA
- Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma
- (2009) F. van Rhee et al. MOLECULAR CANCER THERAPEUTICS
- Role of decorin in the antimyeloma effects of osteoblasts
- (2008) X. Li et al. BLOOD
- CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
- (2008) E. D. Hsi et al. CLINICAL CANCER RESEARCH
- Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies
- (2008) R. Berger et al. CLINICAL CANCER RESEARCH
- Inhibiting Dickkopf-1 (Dkk1) Removes Suppression of Bone Formation and Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma
- (2008) Deborah J Heath et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti–Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma
- (2008) Martha Q. Lacy et al. JOURNAL OF CLINICAL ONCOLOGY
- Small-molecule inhibition of proteasome and silencing by vascular endothelial cell growth factor-specific siRNA induce additive antitumor activity in multiple myeloma
- (2008) Michael Koldehoff et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Bortezomib-Resistant Nuclear Factor- B Activity in Multiple Myeloma Cells
- (2008) S. Markovina et al. MOLECULAR CANCER RESEARCH
- Functions of natural killer cells
- (2008) Eric Vivier et al. NATURE IMMUNOLOGY
- Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma
- (2008) K Hatano et al. ONCOGENE
- MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma
- (2008) M. Jinushi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started